Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Conditions
Interventions
Suptavumab 30 mg/kg
Placebo Matched to Suptavumab
+2 more
Locations
205
United States
Regeneron Investigational Site
Birmingham, Alabama, United States
Regeneron Study Site
Mobile, Alabama, United States
Regeneron Study Site
Little Rock, Arkansas, United States
Regeneron Study Site
Anaheim, California, United States
Regeneron Study Site
Bell Gardens, California, United States
Regeneron Study Site
Dinuba, California, United States
Start Date
July 21, 2015
Primary Completion Date
July 5, 2017
Completion Date
September 26, 2017
Last Updated
November 6, 2018
NCT07220109
NCT07092865
NCT07239583
NCT04732871
NCT06534892
NCT04919109
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions